Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

The team notes that different forms of SCN1B gene expression may result in different outcomes for the therapy. However, the proof-of-concept is the first step toward a gene replacement therapy for ...

Get Instant Summarized Text (Gist) Gene therapy and bone marrow transplantation have shown promise in alleviating symptoms of multiple sulfatase deficiency (MSD), a rare genetic disorder. In mouse ...

The performance of AAV gene-therapy vectors is studied in machine-perfused human livers — and the presence of fatty liver disease makes a difference.

“Every gene therapy company should optimize and develop every technology in their arsenal of viral vectors,” advises Alexandria “Zandy” Forbes, PhD, president and CEO MeiraGTx. She ...